<![CDATA[Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer]]>
When a man with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) walks into clinic today, the default is no longer androgen-deprivation therapy (ADT) alone but ADT plus an androgen-receptor pathway inhibitor (ARPI), with debate now …